enGene Announces Oversubscribed $200 Million Private Placement Financing
Financing included participation from new and existing investors
Pro forma cash and cash equivalents expected to fund current operating plan into 2027
BOSTON and MONTREAL, Feb. 14, 2024 /PRNewswire/ – enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that it has agreed to sell 20 million of its common shares at a price per share of $10.00, representing a 31% premium over the closing price on February 13, 2024. The financing is expected to close on February 16, 2024, subject to customary closing conditions. enGene anticipates the gross proceeds from the private placement to be $200 million, before deducting any offering-related expenses.